New drug shows promise for rare nerve tumors in chinese patients

NCT ID NCT04590235

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times

Summary

This early-stage study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The main goals are to check the drug's safety and how the body processes it, while also measuring if the tumors shrink. Participants take the drug by mouth and are monitored for side effects and tumor changes using MRI scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Shanghai, 200011, China

  • Research Site

    Shanghai, CN-200092, China

Conditions

Explore the condition pages connected to this study.